1. Home
  2. PRTA

as 08-08-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Founded: 2012 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 2
Market Cap: 366.6M IPO Year: N/A
Target Price: $24.29 AVG Volume (30 days): 955.8K
Analyst Decision: Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -5.63 EPS Growth: N/A
52 Week Low/High: $4.32 - $23.66 Next Earning Date: 08-04-2025
Revenue: $10,341,000 Revenue Growth: -95.24%
Revenue Growth (this year): -75.92% Revenue Growth (next year): 122.46%

PRTA Daily Stock ML Predictions

Share on Social Networks: